Dor Capital is a long-term family investment vehicle.
Dor Capital was founded by Mitchell Gold and his three sons, Aidan, Noah and Simon.
After Mitchell lost his mother to cancer at a young age, he went on to develop and gain FDA approval of the world’s first cell therapy for cancer as the CEO of Dendreon. He later founded Alpine Immune Sciences, which was acquired by Vertex Pharmaceuticals for $4.9B in 2024.
Dor Capital is dedicated to investing in a wide range of assets, focused on multi-family real estate, car wash development and emerging medicine and hardware innovation.
Dor is derived from the Hebrew phrase,
“L’dor V’dor”, which means,
“for generations and generations.”
“After losing my mother to breast cancer at the age of four, I learned how fragile and short life can be. It also made me appreciate the value of family.
I have had a successful career building transformative biotech companies for the last 25 years but the opportunity to build an enduring, multi-generational legacy of investments at Dor with my sons is one of the most meaningful endeavors of my career.”
Mitchell Gold, Founder and Managing Partner of Dor Capital